Drug Information

Drug General Information
Drug ID
D00HBR
Former ID
DIB015545
Drug Name
AIKO-150
Synonyms
Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol
Drug Type
Small molecular drug
Indication Opiate dependence [ICD9: 304; ICD10:F11] Phase 1 [522558]
Company
Aiko Biotechnology Inc
Formula
C20H25NO4
Canonical SMILES
c1cc(c2c3c1C[C@@H]1[C@]4([C@@]3([C@H]([C@@H](CC4)O)O2)C<br />CN1CC1CC1)O)O
PubChem Compound ID
5486554
Target and Pathway
Target(s) Mu-type opioid receptor Target Info Antagonist [551690]
KEGG Pathway Neuroactive ligand-receptor interaction
Estrogen signaling pathway
Morphine addiction
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Enkephalin release
Pathway Interaction Database IL4-mediated signaling events
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways TCR Signaling Pathway
GPCRs, Class A Rhodopsin-like
Peptide GPCRs
Opioid Signalling
GPCR ligand binding
GPCR downstream signaling
References
Ref 522558ClinicalTrials.gov (NCT00829777) Safety Study of Intravenous 6??Naltrexol (AIKO-150) in Opioid-Dependent Subjects. U.S. National Institutes of Health.
Ref 551690Clinical pipeline report, company report or official report of signaturerx.